• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
?
-

Resources for You

Avelox (moxifloxacin hydrochloride) Tablets, 400 mg January 2009

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- January 2009

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.


Summary View


 

Sections Modified

Summary of Changes to Contraindications and Warnings

WARNINGS

  • QT prolongation

ADVERSE REACTIONS

ADVERSE EVENTS

  • Post-Marketing Adverse Event Reports

WARNINGS

  • QT prolongation subsection
    • ... (second paragraph)